LeafCann Manufacturing, a subsidiary of LeafCann Group, has gained a licence from the Australian Office of Drug Control to manufacture medical cannabis.
The company said in a statement that this respresents a major milestone, and will lead to construction of “a world-class indoor facility based in South Australia” and to eventually provide medicine for the treatment of chronic pain. According to research by the Brightfield Group, the medical cannabis sector was worth $US 7.7 billion in 2016.
Dr Jaroslav Boublik, Leafcann Group Chief Scientist, said, “Our team is focussed on delivering the highest quality product, focusing on high-tech indoor facilities. This enables us to control all elements, resulting in a pharmaceutical grade product, and ensuring a consistent patient experience, which supported by research and development, will drive clinical acceptance.”
The passage of the Narcotic Drug Amendment in February 2016 allowed Australian cultivation of medical cannabis.
Subscribe to our free @AuManufacturing newsletter here.